BHCライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	2.07M
平均出来高	2.85M
時価総額	3.18B
EPS	$0 ( 2024-02-22 )
次の収益日	( $0.740 ) 2024-05-02
Last Dividend	$1.000 ( 2010-11-10 )
Next Dividend	$0 ( N/A )
P/E	-5.38
ATR14	$0.00800 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Paulson John	Buy	5 890	Common Shares, No Par Value
2024-03-29	Icahn Brett	Buy	3 122	Common Shares, No Par Value
2024-03-29	Robertson Russel C	Buy	2 945	Common Shares, No Par Value
2024-03-29	Wechsler Amy B	Buy	647	Common Shares, No Par Value
2024-02-29	Barresi John S	Buy	39 126	Common Shares, No Par Value

INSIDER POWER
67.94
Last 100 transactions
Buy: 2 132 507 \| Sell: 336 154

ボリューム相関

長: -0.11 (neutral)

短: 0.07 (neutral)

Signal:(46.694) Neutral

Bausch Health Companies 相関

10 最も正の相関
YSAC	0.851
PKE	0.81

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Bausch Health Companies 相関 - 通貨/商品

0.00
( neutral )

0.16
( neutral )

0.00
( neutral )

0.51
( weak )

0.24
( neutral )

Bausch Health Companies 財務諸表

Annual	2023
収益:	$8.76B
総利益:	$6.20B (70.78 %)
EPS:	$-1.620

FY	2023
収益:	$8.76B
総利益:	$6.20B (70.78 %)
EPS:	$-1.620

FY	2022
収益:	$8.12B
総利益:	$5.76B (70.90 %)
EPS:	$-0.590

FY	2021
収益:	$8.43B
総利益:	$6.04B (71.61 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Bausch Health Companies Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bausch Health Companies Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 6.11 - average (70.51%) | Divividend Growth Potential Score: 2.84 - No dividend growth expected in the near future

Information

First Dividend	$0.500	2005-11-28
Last Dividend	$1.000	2010-11-10
Next Dividend	$0	N/A
Payout Date	2010-12-22
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	$6.43	--
Avg. Dividend % Per Year	0.00%	--
Score	3.06	--
Div. Sustainability Score	6.11
Div.Growth Potential Score	2.84
Div. Directional Score	4.48	--

Next Divdend (Est)
(2024-06-07)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.06

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2005	$0.500	3.07%
2006	$0.500	2.01%
2007	$2.00	9.47%
2008	$1.500	11.20%
2009	$0.645	6.68%
2010	$1.280	8.72%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0190	1.500	-0.379	-0.569	[0 - 0.5]
returnOnAssetsTTM	-0.00607	1.200	-0.202	-0.243	[0 - 0.3]
returnOnEquityTTM	0.171	1.500	9.21	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.301	0.800	8.50	6.80	[1 - 3]
quickRatioTTM	0.685	0.800	-0.679	-0.543	[0.8 - 2.5]
cashRatioTTM	0.220	1.500	9.89	10.00	[0.2 - 2]
debtRatioTTM	0.819	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-0.725	1.000	-1.380	-1.380	[3 - 30]
operatingCashFlowPerShareTTM	3.00	2.00	9.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.23	2.00	8.89	10.00	[0 - 20]
debtEquityRatioTTM	-21.91	-1.500	-10.00	10.00	[0 - 2.5]
grossProfitMarginTTM	0.995	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.110	1.000	9.80	9.80	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0489	1.000	-0.839	-0.839	[0.2 - 2]
assetTurnoverTTM	0.320	0.800	-1.199	-0.959	[0.5 - 2]
Total Score				6.11

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-19.16	1.000	-2.04	0	[1 - 100]
returnOnEquityTTM	0.171	2.50	9.49	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.23	2.00	9.26	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.00	2.00	9.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.390	1.500	-5.93	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.125	1.000	9.37	0	[0.1 - 0.5]
Total Score				2.84

Bausch Health Companies

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

リアルタイムの更新： Bausch Health Companies [BHC]

Upcoming Earnings Alert

Bausch Health Companies Dividend Information - Ex Dividend Knight

Dividend Commentary

Top 10 dividend Companies for NYSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)